Christopher E. Loh

Christopher E. Loh


Partner, New York

Christopher Loh practices complex patent litigation in the areas of pharmaceuticals, biotechnology and chemistry. Over the past fifteen years, he has litigated patent cases involving oncology therapies, anti-HIV therapies, anti-hepatitis drugs, antidepressants and statins, including as lead counsel. He has experience arguing before the United States Court of Appeals for the Federal Circuit, and has won on behalf of patent owners in inter partes review proceedings before the Patent Trial and Appeal Board. In addition to his litigation work, Christopher also counsels clients on transactional and patent prosecution issues concerning both small-molecule drugs and biological products such as recombinant antibodies, and advises clients on a range of intellectual property matters including inventorship, trade secrets, and licensing.

Christopher is a frequent author and commentator on intellectual property issues, and has twice won the Burton Award for Legal Achievement in recognition of his exceptional writing. His publications have appeared in Lexology, the National Law Journal, the New York Law Journal, Bloomberg IP and Managing Intellectual Property. He has presented at the BIO IPCC Counsels conference, the New Jersey Intellectual Property Law Association Pharmaceutical/Chemical Patent Practice Update, and has taught for Lawline.

In law school, Christopher served as Notes Editor for the Columbia Business Law Review and also interned at the New York Volunteer Lawyers for the Arts, counseling clients on copyright, trademark and artist rights issues.

Case Highlight

Par Pharmaceutical, Inc. v. Novartis AG, IPR2016-00078 (P.T.A.B. 2016)

In response to an inter partes review petition filed by Par against Novartis’s method-of-use patent for the immunosuppressant drug Zortress® (everolimus), Christopher argued on behalf of Novartis that Par had failed to show that the prior art taught a key element of the patented method of use. The Patent Trial and Appeal Board agreed, and declined to institute inter partes review proceedings against Novartis’s patent.

Representative Matters
  • Novartis Pharmaceuticals Corp. against multiple defendants in cases concerning patents for Novartis’s Alzheimer’s Disease treatment Exelon® Patch (rivastigmine).
  • Novartis AG against Teva Pharmaceuticals USA, Inc. in a case concerning patents for Novartis’s transplant rejection therapy Myfortic® (mycophenolic acid).
  • Genzyme Corporation against multiple defendants in cases concerning patents for Genzyme’s renal disease treatment Hectorol® (doxercalciferol).
  • Novartis Pharmaceuticals Corp. against Mylan Pharmaceuticals, Inc. in a case concerning patents for Novartis’s statin drug Lescol® (fluvastatin).
  • Adams Respiratory Therapeutics, Inc. against Mutual Pharmaceutical Co., Inc. in a case concerning patents for Adams’s antitussive drug Mucinex® (guaifenisen).
  • AstraZeneca Pharmaceuticals LP against multiple defendants in cases concerning patents for AstraZeneca’s anticonvulsive and antidepressant medication Seroquel® (quetiapine).
  • IBM Corp. against Sky Technologies Inc. in a case concerning patents for Sky’s automated negotiation software.
  • Novartis Pharmaceuticals Corp. against Dr. Reddy’s Laboratories, Ltd. in a case concerning patents for Novartis’s antifungal treatment Lamisil® (terbinafine).
  • Bausch & Lomb Inc. against Allergan Inc. in a case concerning patents for Allergan’s glaucoma drug Alphagan® (brimonidine).
  • AstraZeneca AB against Mutual Pharmaceutical Co., Inc. in a case concerning patents for AstraZeneca’s antihypertensive medication Plendil® (felodipine).
Events / Publications